<DOC>
	<DOCNO>NCT02132299</DOCNO>
	<brief_summary>This trial evaluate whether relatively non-immune population endemic country effectively generate significant cellular humoral immune response confer protection P. falciparum infection inoculation aseptic , purified , vialed , metabolically active , non-replicating ( live , radiation attenuate ) Plasmodium falciparum sporozoite ( PfSPZ Vaccine ) administer intravenously ( IV ) .</brief_summary>
	<brief_title>Dose Escalation , Randomized Controlled Trial Evaluate Safety , Immunogenicity Efficacy Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine ( PfSPZ Vaccine ) Tanzanian Adults</brief_title>
	<detailed_description>This single center , Phase 1 , dose escalating , randomize , double blind , control trial . Seventy-three healthy male volunteer , age 18 35 year recruit . The study 5 study group include 49 volunteer intravenously inject PfSPZ Vaccine , 8 control volunteer receive normal saline 16 additional control volunteer recruit time control human malaria infection ( CHMI ) 3 24 week . The control volunteer help good ass occurrence AEs compare background disease pattern occur tropical area , performance vaccine .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male age 18 35 year . Good health status base history clinical examination . Long term permanent resident near DaresSalaam . Able willing complete study visit schedule one year follow period , include hospitalization require protocol compliance . Able willing complete inform consent process conduct English . Demonstrate understand study procedure answer 20 question Protocol &amp; Study Procedures Understanding Checklist correctly maximum two attempt . Agrees inform study doctor medical condition contraindication participation study . Agrees provide contact information study team household member serve emergency contact trial participation . Willing attend study doctor take medication , may prescribe study doctor , study participation . Reachable ( 24/7 ) mobile phone whole study period . Agrees participate another study study period . Agrees donate blood study period . Willing undergo HIV , hepatitis B hepatitis C testing . Willing undergo control human malaria infection ( CHMI ) . History malaria past 5 year . Positive malaria thick blood smear screening . Plans travel outside DaresSalaam Coast Region first 12 month study . Previous receipt investigational malaria vaccine . Antibodies parasites select parasite protein ( ) acceptable cut establish site History arrhythmias prolong QTinterval cardiac disease clinically significant abnormality electrocardiogram ( ECG ) screening . History indication history drug alcohol abuse interfere normal social function . Use chronic immunosuppressive drug , antibiotic , immune modifying drug within three month study enrollment ( inhaled topical corticosteroid allow ) . Ongoing condition could interfere interpretation study result compromise health volunteer . History diabetes mellitus cancer . Body Mass Index ( BMI ) 18 30 kg/m2 . Any clinically significant deviation normal range biochemistry hematology blood test urine analysis electrolyte . Positive HIV , Hepatitis B virus Hepatitis C virus test . Participation clinical study within 30 day prior study enrollment . Known hypersensitivity , allergy , contraindication Coartem速 Malarone速 include treatment take volunteer interfere Coartem速 Malarone速 . Any confirm suspected immunosuppressive immunodeficient condition , include asplenia . Heterozygous homozygous sickle cell homozygous alpha thalassemia . Glucose6phosphate dehydrogenase deficiency Psychiatric condition precludes compliance protocol ; past present psychosis ; disorder require lithium ; within five year prior enrollment , history suicide plan attempt . Any medical , psychiatric , social condition , occupational reason , judgment investigator , contraindication protocol participation impair volunteer 's ability give inform consent , increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data . History 3 immunization within six month administration first dose vaccine . Clinically active tuberculosis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium falciparum malaria</keyword>
	<keyword>PfSPZ Vaccine</keyword>
	<keyword>PfSPZ Challenge</keyword>
	<keyword>Controlled human malaria infection ( CHMI )</keyword>
</DOC>